

PAPER DETAILS

TITLE: P210 breakpoint is associated with less minimal residual disease compared to p190 breakpoint in acute lymphoblastic leukemia patients with Philadelphia chromosome

AUTHORS: Tugçe Nur YIGENOGLU,Taha BAHSI,Haktan ERDEM,Neslihan DUZKALE,Bahar UNCU ULU,Dicle ISKENDER,Merih KIZIL ÇAKIR,Sinan DAL,Fevzi ALTUNTAS

PAGES: 307-311

ORIGINAL PDF URL: <https://dergipark.org.tr/tr/download/article-file/1162631>

P210 breakpoint is associated with less minimal residual disease compared to p190 breakpoint in acute lymphoblastic leukemia patients with Philadelphia chromosome

Philadelphia kromozomu olan akut lenfoblastik lösemi hastalarında p210 kırılma noktası P190 kırılma noktasına göre daha az minimal kalıntı hastalığı ile ilişkilidir

İD Tuğçe Nur Yiğenoğlu¹, İD Taha Bahsi², İD Haktan Bağış Erdem², İD Neslihan Düzkale³,
İD Bahar Uncu Ulu¹, İD Dicle İskender¹, İD Merih Kızıl Çakar¹, İD Mehmet Sinan Dal¹, İD Fevzi Altuntas¹

¹University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey

²University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Genetics, Ankara, Turkey

³University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Genetics, Ankara, Turkey

Cite this article as/ Bu makaleye atf için: Yiğenoğlu TN, Bahsi T, Erdem HB, et al. P210 breakpoint is associated with less minimal residual disease compared to p190 breakpoint in acute lymphoblastic leukemia patients with Philadelphia chromosome. J Health Sci Med 2020; 3(3): 307-311.

ABSTRACT

Introduction: The Philadelphia chromosome is the most common cytogenetic abnormality in adult patients with acute lymphoblastic leukemia. In addition to its role in treatment choice, evaluation of Philadelphia chromosome is also important to monitor the minimal residual disease. In this study, we aim to study the differences of minimal residual disease status between 2 breakpoint regions (p190 and p210) in adult patients with acute lymphoblastic leukemia.

Material and Method: The data of 205 acute lymphoblastic leukemia patients whose genetic evaluations were performed at our center between March 2010 and February 2019 were retrospectively analyzed.

Results: Philadelphia chromosome was observed in 30 (14.6%) patients. In 75% of the patients who had p210 breakpoint at the time of diagnosis, minimal residual disease was negative after 2 cycles of chemotherapy whereas only 42.8% of the patients who had p190 at the time of diagnosis, minimal residual disease was negative after 2 cycles of chemotherapy. The frequency of Philadelphia chromosome was the highest in 51-60 years age group and it was the least in 18-39 age group in adult B cell acute lymphoblastic leukemia patients.

Conclusion: To the best of our knowledge, this is the first study which evaluated the minimal residual disease status of Philadelphia positive acute lymphoblastic leukemia patients by classifying them into 2 groups according to 2 breakpoints (p190 and p210) in the BCR locus. In our study, we found that p190 breakpoint is associated with less minimal residual disease negative status compared to the patients with p210 breakpoint, therefore more augmented therapies may be preferred in patients with p190 breakpoint compared to therapies of patients with p210 breakpoint.

Keywords: Philadelphia chromosome, minimal residual disease, p210 breakpoint, p190 breakpoint

ÖZ

Giriş: Philadelphia kromozomu, akut lenfoblastik lösemili erişkin hastalarda en sık görülen sitogenetik anormalliktir. Philadelphia kromozomunun değerlendirilmesi, tedavi seçimindeki rolüne ek olarak minimal rezidüel hastalığı izlemek için önemlidir. Bu çalışmada akut lenfoblastik lösemili yetişkin hastalarda 2 kırılma noktası (p190 ve p210) arasındaki minimal rezidüel hastalığı durumu farklılıklarını araştırmayı amaçladık.

Gereç ve Yöntem: Mart 2010-Şubat 2019 tarihleri arasında merkezimizde genetik tetkikleri yapılan 205 akut lenfoblastik lösemili hastasının verileri retrospektif olarak incelendi.

Bulgular: 30 hastada (%14,6) Philadelphia kromozomu gözlemlendi. Tanı anında p210 kırılma noktası olan hastaların %75'inde 2 siklus kemoterapi sonrasında minimal rezidüel hastalığı negatif hale gelirken, tanı anında p190 kırılma noktası olan hastaların sadece %42,8'inde 2 siklus kemoterapi sonrasında minimal rezidüel hastalığı negatif hale geldi. Philadelphia kromozomu sıklığı 51-60 yaş grubunda en yüksek, 18-39 yaş grubunda en az idi.

Sonuç: Literatür taramamıza göre bu çalışma, Philadelphia pozitif akut lenfoblastik lösemili hastalarının minimal rezidüel hastalığı durumunu kırılma noktalarına göre (p190 ve p210) 2 gruba ayırarak değerlendiren ilk çalışmadır. Çalışmamızda BCR lokusundaki p190 kırılma noktasının, p210 kırılma noktasına sahip hastalara kıyasla daha az minimal rezidüel hastalığı negatif durum ile ilişkili olduğunu bulduk, bu nedenle p190 kırılma noktası olan hastalarda p210 kırılma noktası olan hastalarda kullanılan tedavilere kıyasla daha fazla yoğun tedaviler tercih edilebilir.

Anahtar Kelimeler: Philadelphia kromozomu, minimal rezidüel hastalık, p210 kırılma noktası, p190 kırılma noktası

Corresponding Author / Sorumlu Yazar: Tuğçe Nur Yiğenoğlu, Sağlık Bilimleri Üniversitesi, Ankara Dr. Abdurrahman Yurtaslan Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji ve Kemik İliği Transplantasyon Merkezi, 06200, Yenimahalle, Ankara, Türkiye

E-mail / E-posta: dr.nuriyigenoglu@gmail.com

Received / Geliş: 12.05.2020 **Accepted / Kabul:** 08.06.2020



INTRODUCTION

Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by abnormal proliferation of lymphoblasts and can be originated from B-cell lineage (B-ALL) or less commonly T-cell lineage (T-ALL). ALL is a heterogeneous disease that has different morphologic, cytogenetic, and molecular subgroups and becomes symptomatic in a short time due to its aggressive nature (1-3). ALL is the most common childhood malignancy, represents about 80% of all childhood leukemias; but only about 20% of adult leukemias. It has a bimodal distribution that has a peak at 4-5 years and 50 years. The incidence is up to 5/100,000 in children and 2/100,000 in adults (4). Diagnosis of ALL depends on the evaluation of morphology, flow cytometry, immunophenotyping, identification of cytogenetic and molecular abnormalities (4).

The pathogenesis of ALL patients involves a complex chain of events that block the proliferation and differentiation of lymphoid precursor cells and drive aberrant cell proliferation and survival. Improvements in the field of genetic revealed that several changes in the genome are required for leukemogenesis (4,5). The characterization of these genetic alterations that required for leukemogenesis has allowed the identification of the genes critical for pathogenesis and prognosis of ALL (6-8). Wiemels et al. (9) showed that there were chromosomal translocations and rearrangements of the TELAML1 fusion gene in neonatal blood cells of identical twin children with ALL, even several years before the onset of the disease and this may be the earliest evidence about the relation between genetic alterations and ALL pathogenesis. Currently, in more than 80% of ALL patients, numerical and structural chromosomal abnormalities can be identified due to the advances in conventional and molecular methods (5,10-12).

The evaluation of genetic alterations is crucial for diagnosis, risk classification and treatment choice (13). World Health Organization (WHO) classification of hematopoietic neoplasms, the category "B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities" has 7 recurrent genetic abnormalities including t(9;22) (q34.1;q11.2), BCR-ABL1; t(v;11q23.3), KMT2A rearranged; t(12;21) (p13.2;q22.1), ETV6-RUNX1; hyperdiploidy; hypodiploidy; t(5;14) (q31.1;q32.3), IL3-IGH; t(1;19) (q23;p13.3); TCF3-PBX1 and 2 provisional entities including BCR-ABL1-like and iAMP21 s14.

The Philadelphia (Ph) chromosome is the most common cytogenetic abnormality in adult patients with ALL and the incidence increases with age. It is observed in 3% of

childhood ALL cases and up to 50% of ALL patients at the age of 50 years and older (15-20). Ph chromosome results from a reciprocal translocation between the Abelson (ABL-1) oncogene on the long arm of chromosome 9 and a breakpoint cluster region (BCR) on the long arm of chromosome 22. Because of this translocation, BCR gene is joined to the ABL oncogene and forms BCR-ABL fusion gene. This fusion gene encodes an oncogenic protein with constitutively active tyrosine kinase activity that interacts with RAS, AKT, and JAK/STAT pathways and contributes to proliferation and tumor growth (21-23). In adult ALL patients with Ph chromosome, approximately 25% have a p210 breakpoint and 75% have a p190 breakpoint in the BCR locus (23).

Ph positive ALL has a high risk for relapse and central nervous system (CNS) involvement, patients typically present with an aggressive clinical course. Historically, patients with Ph positive ALL had an inferior outcome when compared to the patients with Ph negative ALL but the prognosis of Ph positive ALL patients had changed after the introduction of tyrosine kinase inhibitors (TKIs) into clinical practice (24,25). Therefore, evaluation of Ph chromosome at the time of diagnosis is very important since it has an important role in the treatment choice. In addition to its role in treatment choice, evaluation of Ph chromosome is also important to monitor the disease status and minimal residual disease (MRD). MRD monitoring is crucial for early relapse estimation and treatment decisions. Previous studies revealed that 2 breakpoint regions may be associated with different clinical phenotypes in adult ALL patients (26). In this study, we aimed to investigate the differences of MRD status between 2 breakpoint regions (p190 and p210) in adult patients with Ph positive ALL.

MATERIAL AND METHOD

The data of 205 ALL patients whose genetic evaluations were performed at our center between March 2010 and February 2019 were retrospectively analyzed. This study was approved by the university /local human research ethics committee and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was carried out with the permission of Ethics Committee of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Permission granted /Decision number: 04.12.2019/475).

Patients aged between 18-40 years, received DanaFarber chemotherapy protocol, those aged between 41-55 years received HyperCVAD chemotherapy protocol and those at the age of 56 and older and had good performance status received Ewall chemotherapy protocol whereas patients with poor performance status received vincristine and dexamethazone. Performance status was evaluated with Eastern Cooperative Oncology Group (ECOG) and Charlson Comorbidity Index (CCI). Good performance status was accepted as ECOG:0-2 or CCI:1-2 whereas poor performance status was accepted as ECOG:3-4 or CCI>2. MRD status was evaluated after 2 cycles of chemotherapy. 4 log reduction of abnormal transcript number after induction therapy was accepted as MRD negative.

Written informed consent was obtained from all patients before testing for the use of their ribonucleic acid (RNA) samples for research purposes. Total RNA from ethylenediaminetetraacetic acid (EDTA) -anticoagulated peripheral blood was extracted with an RNA extraction kit (QIAamp RNA Blood Mini Kit). RNA was reverse transcribed with an Ipsogen® RT Kit. cDNA was stored at -20 °C. BCR-ABL1 cDNA was performed on Qiagene Rotor-Gene-Q with TaqMan probes, according to manufacturer's instructions. Each Ipsogen BCR-ABL1 Mbcr Kit provides four standard dilutions for ABL and five standard dilutions for Mbcr. Use of the Ipsogen BCR-ABL1 Mbcr kits enables detection and quantification of BCR-ABL1 and ABL transcripts. The reaction was initiated according to the optimized protocols defined by the manufacturer.

The statistical analyses were performed with SPSS V21.0 (SPSS Inc., Chicago, IL) software. Descriptive statistics were used to summarize the data.

RESULTS

Two hundred five patients with B cell ALL were included in the study. Ph chromosome was observed in 30 (14.6%) patients. In adult ALL patients with Ph chromosome 14 (53.3%) had p210 breakpoint and 16 (46.7%) had p190 breakpoint in the BCR locus. There was not any patients who had both p190 and p210 breakpoints. Median age of the patients with Ph chromosome was 56. The characteristics of the patients with Ph positive ALL is given in **Table 1**. The frequency of Ph chromosome was the highest in 51-60 years age group and it was the least in 18-39 years age group in adult B cell ALL patients. The frequency of Ph chromosome according to the age groups is given in **Table 2**. In 75% of the patients who had p210 at the time of diagnosis, MRD was negative after 2 cycles of chemotherapy whereas only 42.8% of the patients who had p190 at the time of diagnosis, MRD was negative after 2 cycles of chemotherapy.

Table 1. The characteristics of patients with Ph positive ALL

	p210 positive	p190 positive	Ph Chromosome
n	16	14	30
Gender	7 female	7 female	14 female
	9 male	7 male	16 female
Median age	55	56	56
	(range 18-66)	(range 18-76)	(range 18-76)
Ph Chromosome: Philadelphia Chromosome			

Table 2. The frequency of Ph chromosome according to age groups

Age group	n	p210 positive	p190 positive	Ph Chromosome
18-39	96	4	5	9 (9.3%)
40-50	39	3	2	5 (12.8%)
51-60	38	6	5	11 (28.9%)
>60	32	3	2	5 (15.6%)
≥18	205	16	14	30 (14.6%)
Ph Chromosome: Philadelphia Chromosome				

DISCUSSION

ALL arises from recurrent genetic alterations that block precursor B and T cell differentiation (22). The etiology of ALL has been under investigation for decades but the exact cause is still unknown (27). Genetic alterations are observed in approximately 75% of patients with ALL (20). These genetic alterations influence the prognosis and therapeutic approach (20). ALL has a mean survival of 35% in patients aged between 18 and 60 years (28). Because of this poor survival, markers that can be translated to therapeutic targets are very important (29). Nowell and Hungerford (30) described the translocation between chromosomes 9 and 22 leading to the short chromosome 22. Observation of the role of BCR-ABL fusion gene in the leukemogenesis led to the development of a number of TKIs for the treatment of Ph positive B-ALL (31).

In the study conducted by Bartram et al. (3) Ph chromosome was found in 25% of adult ALL patients and up to 50% in older ALL patients. In the study conducted by Azevedo et al. (32) Ph chromosome was found in 34% of Brazilian adult patients with ALL. Gleier et al. (24) showed that 37% of 478 adult ALL patients had BCR-ABL fusion gene. In our study, Ph chromosome was found in 14.6% of adult ALL patients and 15.6% of B ALL patients over 60 years.

The prevalence of genetic alterations varies according to age groups (13). In our study, we observed that Ph chromosome was most common in 51-60 years age group (28.9%) and was observed only in 9.3% of ALL patients in 18-39 years age group.

Nashed et al. (23) observed that in adult ALL patients with Ph chromosome, approximately 25% had p210 breakpoint and 75% had a p190 breakpoint in the BCR locus. In the study conducted by Gleier et al. (24) in patients with Ph chromosome, 77% had p190 breakpoint, 20% had p210 breakpoint and 3% had both isoforms. Dombret et al. (33) found that in patients with Ph chromosome, 68% had p190 breakpoint, 28% had p210 breakpoint and 4% had both isoforms. In our study, in adult ALL patients with Ph chromosome 53.3% had p210 breakpoint and 46.7% had p190 breakpoint in the BCR locus. There was not any patients who had both p190 and p210 breakpoints.

MRD monitoring is very important for both pediatric and adult ALL (5). In our study, in 75% of patients who had p210 breakpoint in the BCR locus at the time of diagnosis, p210 breakpoint could not be detected after 2 cycles of treatment. In 42.8% of patients who had p190 breakpoint in the BCR locus at the time of diagnosis, p190 could not be detected after 2 cycles of treatment.

CONCLUSION

In conclusion, genetic evaluation of ALL patients is very important to plan treatment approaches. Ph chromosome can be observed in up to 1/3 of patients in 51-60 years age group. There is quite limited data about MRD evaluations in ALL patients with Ph chromosome and to our knowledge this is the first study which evaluated the MRD status of Ph positive ALL patients by classifying them into 2 groups according to 2 isoforms (p190 and p210). In our study, we found that p190 breakpoint is associated with less MRD negative status compared to the patients with p210 breakpoint in the BCR locus. As p190 breakpoint is associated with less MRD negative status compared to the patients with p210 breakpoint in the BCR locus, more augmented therapies may be preferred in patients with p190 breakpoint compared to therapies of patients with p210 breakpoint. Further prospective, randomized studies are needed about the relation between MRD status and Ph chromosome isoforms.

Abbreviations: **ABL:** Abelson; **ALL:** Acute lymphoblastic leukemia; **BCR:** Breakpoint cluster region; **CNS:** Central nervous system; **EDTA:** Ethylenediaminetetraacetic acid; **MRD:** Minimal residual disease; **Ph:** Philadelphia; **RNA:** Ribonucleic acid; **TKI:** Tyrosine kinase inhibitor; **WHO:** World Health Organization.

ETHICAL DECLARATIONS

Ethics Committee Approval: The study was carried out with the permission of Ethics Committee of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (Permission granted: 04.12.2019, Decision number: 475).

Informed Consent: Because the study was designed retrospectively, no written informed consent form was obtained from patients.

Referee Evaluation Process: Externally peer-reviewed.

Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

Author Contributions: All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

1. Fey MF, Buske C. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013; 24: vi138-43.
2. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. *Blood Cancer J* 2016; 6: e441.
3. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* 1983; 306: 277-80.
4. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. *Mayo Clin Proc* 2005; 80: 1517-27.
5. Usvasalo A, Rätty R, Harila-Saari A, et al. Acute lymphoblastic leukemias with normal karyotypes are not without genomic aberrations. *Cancer Genet Cytogenet* 2009; 192: 10-7.
6. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. *N Engl J Med* 2004; 350: 1535-48.
7. Rowley JD. The critical role of chromosome translocations in human leukemias. *Annu Rev Genet* 1998; 32: 495-519.
8. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. *J Clin Oncol* 2005; 23: 6306-15.
9. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. *Lancet* 1999; 354: 1499-503.
10. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. *Nat Rev Clin Oncol* 2015; 12: 344-57.
11. Bacher U, Kohlmann A, Haferlach T. Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. *Cancer Treat Rev* 2010; 36: 637-46.
12. Bungaro S, Dell'Orto MC, Zangrando A, et al. Integration of genomic and gene expression data of childhood ALL with-out known aberrations identifies subgroups with specific genetic hallmarks. *Genes Chromosomes Cancer* 2009; 48: 22-38.
13. Iacobucci I, Mullighan C. Genetic basis of acute lymphoblastic leukemia. *J Clin Oncol* 2017; 35: 975-83.

14. Arber D, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391-405
15. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. *Blood* 1999; 93: 3983-93.
16. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. *Cancer* 2003; 98: 1337-54.
17. Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel E. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. *Blood* 2008; 112: 918-9.
18. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. *Leukemia* 1991; 5: 196-9.
19. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006; 354: 166-78.
20. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. *Cancer Cell* 2002; 2: p.437-45.
21. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 1973; 243: 290-3.
22. Teitell MA, Pandolfi PP. Molecular genetics of acute lymphoblastic leukemia. *Annu Rev Pathol* 2009; 4: 175-98.
23. Nashed AL, Rao KW, Gulley ML. Clinical applications of BCR-ABL molecular testing in acute leukemia. *J Mol Diagn* 2003; 5: 63-72.
24. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. *Blood* 2002; 99: 1536-43.
25. Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult acute lymphoblastic leukemia. *Curr Opin Oncol* 2006; 18: 652-9.
26. Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive b-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. *Cancer* 2011; 117: 4009-17
27. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. *Cancer* 2008; 112: 416-32.
28. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. *J Clin Oncol* 2011; 29: 532-43.
29. Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. *Clin Cancer Res* 2011; 17: 396-400.
30. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. *J Natl Cancer Inst* 1960; 25: 85-109.
31. Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood* 2019; 133: 130-6. (doi: 10.1182/blood-2018-08-832105).
32. de França Azevedo I, da Silva Júnior RM, de Vasconcelos AV, et al. Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia. *Rev Bras Hematol Hemoter* 2014; 36: 351-5.
33. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia results of the prospective multicenter LALA-94 trial. *Blood* 2002; 100: 2357-66.